Oxidative biotransformation of the antitumour agent elliptinium acetate: Structural characterization of its human and rat urinary metabolites
- 1 January 1987
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 5 (4) , 341-351
- https://doi.org/10.1016/0731-7085(87)80040-7
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Requirement for the presence of a 2′-α-OH group for the arylation of purine nucleosides by elliptinium acetate, an antitumour agentJournal of the Chemical Society, Chemical Communications, 1985
- Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.Proceedings of the National Academy of Sciences, 1984
- Human and rat urinary metabolites of the antitumor drug celiptium ® (N2-methyl-9-hydroxyellipticinium acetate, NSC 264137). Identification of cysteine conjugates supporting the “biooxidative alkylation” hypothesisBiochemical Pharmacology, 1983
- o-Quinone formation in the biochemical oxidation of the antitumor drug N2-methyl-9-hydroxyellipticinium acetateJournal of Medicinal Chemistry, 1983
- Unexpected regiospecific alkylation of the antitumor agent N2-methyl-9-hydroxyellipticinium acetate with N, O or S donorsTetrahedron Letters, 1983
- Metabolism of the anti-tumour drugsN2-methyl-9-hydroxyellipticinium acetate (NSC 264137) andN2-methyl-9-hydroxyolivacinium acetate in the rat: preliminary identification of biliary 9-(O)-glucuronide and 10-(S)-glutathione conjugatesXenobiotica, 1983
- Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study)European Journal of Cancer and Clinical Oncology, 1982
- Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide systemJournal of Medicinal Chemistry, 1981
- Antitumor Activity, Pharmacology, and Toxicity of Ellipticines, Ellipticinium, and 9-Hydroxy Derivatives: Preliminary Clinical Trials of 2-Methyl-9-Hydroxy Ellipticinium (NSC 264-137)Published by Springer Nature ,1980
- A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational Design of Anticancerous Drugs in the Series of DNA Intercalating DrugsProceedings of the National Academy of Sciences, 1974